

**HtrA2 (OMI) Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP1333b****Specification**

---

**HtrA2 (OMI) Antibody (C-term) Blocking Peptide - Product Information**

Primary Accession [O43464](#)  
Other Accession [NP\\_659540](#)

**HtrA2 (OMI) Antibody (C-term) Blocking Peptide - Additional Information**

**Gene ID** 27429

**Other Names**

Serine protease HTRA2, mitochondrial, High temperature requirement protein A2, HtrA2, Omi stress-regulated endoprotease, Serine protease 25, Serine proteinase OMI, HTRA2, OMI, PRSS25

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP1333b](/product/products/AP1333b) was selected from the OMI region of human HtrA2 (OMI). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**HtrA2 (OMI) Antibody (C-term) Blocking Peptide - Protein Information**

**Name** HTRA2

**Synonyms** OMI, PRSS25

**Function**

Serine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive.

**Cellular Location**

Mitochondrion intermembrane space. Mitochondrion membrane; Single-pass membrane protein  
Note=Predominantly present in the intermembrane space. Released into the cytosol following apoptotic stimuli, such as UV treatment, and stimulation of mitochondria with caspase-8 truncated BID/tBID

**Tissue Location**

[Isoform 1]: Ubiquitously expressed.

**HtrA2 (OMI) Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**HtrA2 (OMI) Antibody (C-term) Blocking Peptide - Images****HtrA2 (OMI) Antibody (C-term) Blocking Peptide - Background**

Insulin-like growth factors (IGFs) stimulate the proliferation and differentiation of a vast number of cell types. The action of the growth factors is mediated and controlled by a complex system of components, including several proteases that cleave the IGF-Binding Proteins. HtrA1 is a 480 aa protein that contains an N-terminus homologous to MAC25 (IGFBP7) with a conserved Kazal-type serine protease inhibitor motif, as well as a C-terminal PDZ domain. Semiquantitative RT-PCR and immunoblot analyses showed an approximately 7-fold increase of PRSS11 in osteoarthritis cartilage compared with controls. HTRA2 is released from mitochondria and inhibits the function of XIAP by direct binding in a way similar to SMAC. Moreover, when overexpressed extramitochondrially, HTRA2 induced atypical cell death, which was neither accompanied by a significant increase in caspase activity nor inhibited by caspase inhibitors, including XIAP. A catalytically inactive mutant of HTRA2, however, did not induce cell death. Suzuki et al. (2001) concluded that HTRA2 is a SMAC-like inhibitor of IAP (inhibitor of apoptosis proteins) activity with a serine protease-dependent cell death-inducing activity.

**HtrA2 (OMI) Antibody (C-term) Blocking Peptide - References**

Gray C.W., et al. Eur. J. Biochem. 267:5699-5710(2000)Verhagen A.M., et al. J. Biol. Chem. 277:445-454(2002)